The U.S. Food and Drug Administration (FDA) has accepted a request by Acadia Pharmaceuticals‘ that Nuplazid (pimavanserin) be approved for a new indication: the treatment of delusions and hallucinations associated with dementia-related psychosis. The company’s supplemental new drug application, which was submitted in June, was granted standard review status. The FDA’s decision is expected by April 3, 2021. No issues were found with the application, and the agency is not planning to request an advisory committee…
You must be logged in to read/download the full post.
The post FDA to Consider Nuplazid to Treat Dementia-related Psychosis appeared first on BioNewsFeeds.